Thrombocytopenia Purpura

Recombinant Interleukin-11 Not Effective For Refractory Patients

Published in Blood Weekly, April 12th, 2001

by Michael Greer, staff medical writer - Despite its platelet-stimulating effects, recombinant human interleukin-11 (rhIL-11) does not show promising results for the treatment of refractory immune thrombocytopenia purpura (ITP) patients, researchers report.

"Platelet production is decreased in certain cases of refractory ITP," explained J.B. Bussel and colleagues at Cornell University. "IL-11 stimulates megakaryocytopoiesis in vitro and was licensed for its clinical effects to ameliorate chemotherapy-induced thrombocytopenia."

However, Bussel et al. found that refractory ITP patients realized little if any benefit from rhIL-11 treatment, at the cost...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2001-04-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry